Advertisement

Topics

PubMed Journals Articles About "Guanfacine Extended Release Tablets Placebo Comparator Attention Deficit" RSS

22:49 EST 17th January 2019 | BioPortfolio

Guanfacine Extended Release Tablets Placebo Comparator Attention Deficit PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Guanfacine Extended Release Tablets Placebo Comparator Attention Deficit articles that have been published worldwide.

More Information about "Guanfacine Extended Release Tablets Placebo Comparator Attention Deficit" on BioPortfolio

We have published hundreds of Guanfacine Extended Release Tablets Placebo Comparator Attention Deficit news stories on BioPortfolio along with dozens of Guanfacine Extended Release Tablets Placebo Comparator Attention Deficit Clinical Trials and PubMed Articles about Guanfacine Extended Release Tablets Placebo Comparator Attention Deficit for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Guanfacine Extended Release Tablets Placebo Comparator Attention Deficit Companies in our database. You can also find out about relevant Guanfacine Extended Release Tablets Placebo Comparator Attention Deficit Drugs and Medications on this site too.

Showing "Guanfacine extended release tablets Placebo comparator Attention Deficit" PubMed Articles 1–25 of 11,000+

Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial.

This study evaluated the effect of the alpha-2A-adrenoceptor agonist guanfacine on prefrontally mediated cognitive functions, as well as quality of life and global function in healthy older participants. One hundred twenty-three participants aged 75 years and older were randomly assigned to guanfacine 0.5 mg, 0.1 mg, or placebo daily for 12 weeks. The primary outcome measure was the change in z-score for 6 prefrontal executive function tasks over 12 weeks (PEF6). Neither dose of guanfacine improved PEF6...


Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder.

A methylphenidate (MPH) extended-release orally disintegrating tablet (MPH XR-ODT) formulation was recently approved for attention-deficit/hyperactivity disorder treatment in children 6 to 17 years of age. This analysis sought to develop a population pharmacokinetic (PK)/pharmacodynamic (PD) model to describe MPH XR-ODT PD-response data in a classroom study and use the model to simulate PD responses for a range of body weights and doses.

Cardiovascular Effects of Drugs Used to Treat Attention Deficit/Hyperactivity Disorder Part 1: Epidemiology, Pharmacology, and Impact on Hemodynamics and Ventricular Repolarization.

Attention-deficit/hyperactivity disorder (ADHD) is a clinical syndrome characterized by persistent inattention, impulsivity and hyperactivity. It is most commonly encountered in children and adolescents, but may persist into adulthood. A variety of psychostimulant and non-psychostimulant medications have proven to be successful in reducing inattention, impulsivity and hyperactivity in those with ADHD. Psychostimulants used to treat ADHD include methylphenidate and related drugs and various amphetamine prepa...


Assessment of Taste and Grittiness of Riomet ER Strawberry, Riomet ER Grape, Riomet Cherry, and Metformin Immediate-Release Tablets in Healthy Subjects.

This study was conducted to evaluate the taste and grittiness of two formulations of Riomet ER (metformin hydrochloride for extended release [ER] oral suspension 100 mg/mL) differing only in their flavoring agents (strawberry and grape) in comparison with two commercially available immediate-release (IR) formulations of metformin, Riomet Cherry (metformin hydrochloride oral solution 500 mg/5 mL) and metformin IR tablets (metformin hydrochloride IR tablets 500 mg), in healthy human subjects aged 10-70 y...

Modified in vitro release of melatonin loaded in nanofibrous electrospun mats incorporated into mono-layered and three-layered tablets.

Modified release tablet formulations with melatonin (MLT) are clinically more useful in initiating and maintaining sleep in elderly insomniacs, compared with those designed for immediate release. Aiming at the modified release of MLT, mono-layered and three-layered tablets, incorporating nanofibrous mats composed of cellulose acetate (CA) and polyvinylpyrrolidone (PVP) loaded with MLT, were prepared and studied. In vitro dissolution profiles of MLT in gastrointestinal-like fluids, revealed tableting pressur...

Does L-Methylfolate Supplement Methylphenidate Pharmacotherapy in Attention-Deficit/Hyperactivity Disorder?: Evidence of Lack of Benefit From a Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Interventions for attention-deficit/hyperactivity disorder (ADHD) may be inadequate for some patients. There is evidence that supplementation with L-methylfolate augments antidepressant agent effects and thus might also augment ADHD treatment effects by a common catecholaminergic mechanism.

Novel immediate/sustained-release formulation of acetaminophen-ibuprofen combination (Paxerol®) for severe nocturia associated with overactive bladder: A multi-center, randomized, double blinded, placebo-controlled, 4-arm trial.

To determine short-term efficacy and safety of Paxerol®, novel immediate:sustained (50%:50%) release tablets containing 325 mg acetaminophen and 150 mg ibuprofen per tablet.

Effects of Long-Term Use of Prescription Methylphenidate on Myocardial Performance in Children with Attention-Deficit/Hyperactivity Disorder: A Tissue Doppler Imaging Study.

Many children diagnosed with attention-deficit/hyperactivity disorder are treated with methylphenidate (MPH). The purpose of this study was to evaluate the relationship between long-term use of osmotic-release oral system methylphenidate (OROS MPH) and cardiac functions.

Extrusion 3D Printing of Paracetamol Tablets from a Single Formulation with Tunable Release Profiles Through Control of Tablet Geometry.

An extrusion-based 3D printer was used to fabricate paracetamol tablets with different geometries (mesh, ring and solid) from a single paste-based formulation formed from standard pharmaceutical ingredients. The tablets demonstrate that tunable drug release profiles can be achieved from this single formulation even with high drug loading (> 80% w/w). The tablets were evaluated for drug release using a USP dissolution testing type I apparatus. The tablets showed well-defined release profiles (from immediat...

Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial.

To evaluate the relationship between symptom and functional improvement and remission in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) enrolled in an 11-week open-label dose-optimization phase of an methylphenidate extended release (MPH-MLR) pivotal study.

Sugar consumption and attention-deficit/hyperactivity disorder (ADHD): A birth cohort study.

Attention-deficit/hyperactivity disorder (ADHD) is characterized by persistent symptoms of lack of attention, impulsivity and hyperactivity. The association between nutritional exposures and ADHD has been investigated and some studies have identified adverse effects from higher intake of sugar. The objective of the present study was to evaluate the association between change in sugar consumption between 6 and 11 years of age and incidence of attention-deficit/hyperactivity disorder (ADHD).

Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial assessing Efficacy and Safety.

Several single-site alcohol treatment clinical trials have demonstrated efficacy for immediate-release (IR) gabapentin in reducing drinking outcomes among individuals with alcohol dependence. The purpose of this study was to conduct a large, multisite clinical trial of gabapentin enacarbil extended-release (GE-XR) (HORIZANT ), a gabapentin prodrug formulation, to determine its safety and efficacy in treating alcohol use disorder (AUD).

Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis.

Posaconazole delayed-release tablets offer better bioavailability than the liquid suspension, but no post-marketing data are available in immunocompetent hosts such as those with chronic pulmonary aspergillosis (CPA).

On-demand manufacturing of immediate release levetiracetam tablets using pressure-assisted microsyringe printing.

Fast and accurate manufacturing of individually tailored solid dosage forms is one of the main challenges for personalized medicine. The use of 3D printers has recently been studied to determine their suitability for personalized drug manufacturing. In the current work, formulations free of organic solvents were developed for a pressure-assisted microsyringe printing method (PAM). The water soluble polymer polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG) was used as matrix, while levetiraceta...

Patterns of Immediate-Release and Extended-Release Opioid Analgesic Use in the Management of Chronic Pain, 2003-2014.

Many stakeholders are working to improve the safe use of immediate-release (IR) and extended-release/long-acting (ER/LA) opioid analgesics. However, little information exists regarding the relative use of these 2 formulations in chronic pain management.

Predicting attention deficit hyperactivity disorder using pregnancy and birth characteristics.

The aim of this study was to evaluate maternal, prenatal, perinatal, and postpartum parameters as risk factors for the later development of an attention deficit hyperactivity disorder (ADHD) in the child.

The origin of the centrality deficit in individuals with attention-deficit/hyperactivity disorder.

Studies have shown that skilled and disabled readers recall central ideas, which are important to the overall comprehension of the text, to a greater extent than peripheral, less important ideas after reading. However, readers with attention-deficit/hyperactivity disorder (ADHD) recall significantly fewer central ideas than skilled readers. The present study was designed to examine whether difficulties in identifying, attending, and/or retrieving central ideas underlie their centrality deficit.

Association between sensory modulation and daily activity function of children with attention deficit/hyperactivity disorder and children with typical development.

The severity of the functional difficulties of children with attention-deficit/hyperactivity disorder (ADHD) is heterogeneous and may be affected by measurable factors.

The Effects of Fillers and Binders on the Accuracy of Tablet Subdivision.

The effects of excipients on the accuracy of tablet subdivision are severely underinvestigated. In this study, placebo tablets were prepared using a combined mixture design of fillers and binders to evaluate the effect of these excipients on subdivision accuracy. The responses assessed were mass loss, mass variation, tablet fragmentation, and increased friability. Dicalcium phosphate dihydrate (DCP) gave rise to more uniform and denser tablets than microcrystalline cellulose (MCC), thus resulting in greater...

Extended release versus immediate release tacrolimus in kidney transplant recipients: a systematic review and meta-analysis.

To compare the estimated glomerular filtration rate (eGFR) at 12 months together with other outcomes among adult kidney transplant recipients (KTRs) who received extended release, once daily tacrolimus (ER-Tac) compared to those who received the immediate release, twice daily tacrolimus (IR-Tac) administration.

Combination of 3D printing technologies and compressed tablets for preparation of riboflavin floating tablet-in-device (TiD) systems.

Gastric floating tablets have the functions of long-term gastric retention, sustained release and improving bioavailability though the floating time and sustained release are usually not satisfied. Here we designed a novel gastric floating system by combining compressed tablets with 3D printed devices, wherein a riboflavin tablet was contained into a device, named as tablet-in-device (TiD) systems. Commercial poly(lactic acid) filaments were used for 3D printing of the body and cap of the device. Four types...

Effect of lignin as natural polymer on the release rate of acetylsalicylic acid tablets.

The main focus here is on the improvement of formulations utilising non-conventional bio-based excipients to improve tablet release rates. Two different formulations were considered. The first formulation contains Alcell lignin, lactose monohydrate and microcrystalline cellulose as excipients and acetylsalicylic acid (aspirin) as active pharmaceutical ingredient (API). The second formulation contains lactose monohydrate and microcrystalline cellulose as excipients and aspirin as API. The prepared formulatio...

Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice.

Up to 50% of Crohn's disease and ulcerative colitis patients suffer from ileo-colonic inflammation. Topically delivered budesonide is an effective treatment but in vitro as well as clinical data suggest that oral formulations currently used in clinical practice are not optimal to treat the ileo-colon. The aim of this in vitro study was to develop ileo-colonic-targeted zero-order sustained-release tablets containing 3 mg or 9 mg budesonide. Targeted delivery was achieved by coating the tablets with the ColoP...

Extended release bupivacaine formulations for postoperative analgesia: an update.

New formulations of local anesthetics with sustained release and longer duration of action are being developed to improve patient outcomes following surgery. This review summarizes the efficacy and safety of the three most recently developed extended-release formulations of the local anesthetic, bupivacaine.

New Approach for the Application of USP Apparatus 3 in Dissolution Tests: Case Studies of Three Antihypertensive Immediate-Release Tablets.

The USP Apparatus 3 is a compendial dissolution Apparatus that has been mainly used to assess the performance of modified-release drug products. However, this Apparatus can be applied to dissolution testing of immediate-release tablets as well, with several advantages such as lower consumption of dissolution media, reduced setup time in quality control routine, and minimized hydrodynamic issues. In this work, three immediate-release (IR) tablets containing antihypertensive drugs of different Biopharmaceutic...


Advertisement
Quick Search
Advertisement
Advertisement